Primary Results From Impassion131, a Double-Blind Placebo-Controlled Randomized Phase 3 Trial of First-Line Paclitaxel +/- Atezolizumab for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [1] Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
    Miles, D.
    Gligorov, J.
    Andre, F.
    Cameron, D.
    Schneeweiss, A.
    Barrios, C.
    Xu, B.
    Wardley, A.
    Kaen, D.
    Andrade, L.
    Semiglazov, V
    Reinisch, M.
    Patel, S.
    Patre, M.
    Morales, L.
    Patel, S. L.
    Kaul, M.
    Barata, T.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2021, 32 (08) : 994 - 1004
  • [2] Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first- line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
    Miles, D. W.
    Gligorov, J.
    Andre, F.
    Cameron, D.
    Schneeweiss, A.
    Barrios, C. H.
    Xu, B.
    Wardley, A. M.
    Kaen, D.
    Andrade, L.
    Semiglazov, V.
    Reinisch, M.
    Patre, M.
    Morales, L.
    Russell, K.
    Donica, M.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1147 - S1148
  • [3] Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
    Schmid, Peter
    Rugo, Hope S.
    Adams, Sylvia
    Schneeweiss, Andreas
    Barrios, Carlos H.
    Iwata, Hiroji
    Dieras, Veronique
    Henschel, Volkmar
    Molinero, Luciana
    Chui, Stephen Y.
    Maiya, Vidya
    Husain, Amreen
    Winer, Eric P.
    Loi, Sherene
    Emens, Leisha A.
    LANCET ONCOLOGY, 2020, 21 (01): : 44 - 59
  • [4] Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
    Dent, Rebecca
    Oliveira, Mafalda
    Isakoff, Steven J.
    Im, Seock-Ah
    Espie, Marc
    Blau, Sibel
    Tan, Antoinette R.
    Saura, Cristina
    Wongchenko, Matthew J.
    Xu, Na
    Bradley, Denise
    Reilly, Sarah-Jayne
    Mani, Aruna
    Kim, Sung-Bae
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (02) : 377 - 386
  • [5] Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
    Rebecca Dent
    Mafalda Oliveira
    Steven J. Isakoff
    Seock-Ah Im
    Marc Espié
    Sibel Blau
    Antoinette R. Tan
    Cristina Saura
    Matthew J. Wongchenko
    Na Xu
    Denise Bradley
    Sarah-Jayne Reilly
    Aruna Mani
    Sung-Bae Kim
    Breast Cancer Research and Treatment, 2021, 189 : 377 - 386
  • [6] IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer
    Dent, R.
    Andre, F.
    Goncalves, A.
    Martin, M.
    Schmid, P.
    Schuetz, F.
    Kuemmel, S.
    Swain, S. M.
    Bilici, A.
    Loirat, D.
    Valencia, R. Villalobos
    Im, S. -A
    Park, Y. H.
    De Laurentis, M.
    Colleoni, M.
    Guarneri, V.
    Bianchini, G.
    Li, H.
    Machackova, Z. Kirchmayer
    Mouta, J.
    Deurloo, R.
    Gan, X.
    Fan, M.
    Mani, A.
    Swat, A.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2024, 35 (07) : 630 - 642
  • [7] First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
    Emens, L. A.
    Adams, S.
    Barrios, C. H.
    Dieras, V
    Iwata, H.
    Loi, S.
    Rugo, H. S.
    Schneeweiss, A.
    Winer, E. P.
    Patel, S.
    Henschel, V
    Swat, A.
    Kaul, M.
    Molinero, L.
    Patel, S.
    Chui, S. Y.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2021, 32 (08) : 983 - 993
  • [8] Double-Blind Placebo-Controlled Randomized Phase III Trial Evaluating First-Line Ipatasertib Combined With Paclitaxel for PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer: Primary Results From IPATunity130 Cohort A
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 8 - 8
  • [9] Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Kim, Sung-Bae
    Dent, Rebecca
    Im, Seock-Ah
    Espie, Marc
    Blau, Sibel
    Tan, Antoinette R.
    Isakoff, Steven J.
    Oliveira, Mafalda
    Saura, Cristina
    Wongchenko, Matthew J.
    Kapp, Amy V.
    Chan, Wai Y.
    Singel, Stina M.
    Maslyar, Daniel J.
    Baselga, Jose
    LANCET ONCOLOGY, 2017, 18 (10): : 1360 - 1372
  • [10] IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).
    Dent, Rebecca
    Andre, Fabrice
    Goncalves, Anthony
    Kummel, Sherko
    Martin, Miguel
    Schmid, Peter
    Schuetz, Florian
    Swain, Sandra M.
    Easton, Valerie
    Pollex, Erika
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345